Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

Next Previous
Trial Profile

An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacituzumab govitecan (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ASCENT
  • Sponsors Gilead Sciences; Immunomedics

Most Recent Events

  • 09 Dec 2023 Results of pooled analysis from TROPiCS-02, IMMU-132-01, and ASCENT presented at the 46th Annual San Antonio Breast Cancer Symposium.
  • 09 Nov 2022 Results(n=479) assessing Health Utilities Associated With Sacituzumab Govitecan (SG) for Treating Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
  • 18 Oct 2022 Results (n=419) of an analysis assessing health-related quality of life published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top